Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | PHLDB2 | Human | 1,2-dimethylhydrazine | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of PHLDB2 mRNA | CTD | PMID:22206623 | PHLDB2 | Human | 1,2-dimethylhydrazine | multiple interactions | ISO | Phldb2 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of PHLDB2 mRNA | CTD | PMID:22206623 | PHLDB2 | Human | 17beta-estradiol | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Estradiol results in decreased expression of PHLDB2 mRNA | CTD | PMID:32145629 | PHLDB2 | Human | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | EXP | | 6480464 | Dihydrotestosterone results in increased expression of PHLDB2 mRNA | CTD | PMID:29581250 | PHLDB2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PHLDB2 mRNA | CTD | PMID:19770486 and PMID:33956508 | PHLDB2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PHLDB2 mRNA | CTD | PMID:32109520 and PMID:33387578 | PHLDB2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Phldb2 (Mus musculus) | 6480464 | [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of PHLDB2 mRNA | CTD | PMID:25975270 | PHLDB2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of PHLDB2 mRNA | CTD | PMID:20106945 and PMID:21632981 | PHLDB2 | Human | 2-hydroxypropanoic acid | increases expression | EXP | | 6480464 | Lactic Acid results in increased expression of PHLDB2 mRNA | CTD | PMID:30851411 | PHLDB2 | Human | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | Phldb2 (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in decreased expression of PHLDB2 mRNA | CTD | PMID:26251327 | PHLDB2 | Human | 4,4'-sulfonyldiphenol | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | bisphenol S results in increased expression of PHLDB2 mRNA | CTD | PMID:30951980 | PHLDB2 | Human | 4,4'-sulfonyldiphenol | decreases methylation | EXP | | 6480464 | bisphenol S results in decreased methylation of PHLDB2 gene | CTD | PMID:31601247 | PHLDB2 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Fenretinide results in increased expression of PHLDB2 mRNA | CTD | PMID:28973697 | PHLDB2 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of PHLDB2 mRNA | CTD | PMID:24780913 and PMID:25825206 | PHLDB2 | Human | aflatoxin B1 | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Aflatoxin B1 results in increased expression of PHLDB2 mRNA | CTD | PMID:19770486 | PHLDB2 | Human | aflatoxin B1 | decreases methylation | EXP | | 6480464 | Aflatoxin B1 results in decreased methylation of PHLDB2 gene | CTD | PMID:27153756 | PHLDB2 | Human | antirheumatic drug | increases expression | EXP | | 6480464 | Antirheumatic Agents results in increased expression of PHLDB2 mRNA | CTD | PMID:24449571 | PHLDB2 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of PHLDB2 mRNA | CTD | PMID:33212167 | PHLDB2 | Human | arsenous acid | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of PHLDB2 mRNA | CTD | PMID:20458559 | PHLDB2 | Human | atrazine | affects methylation | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Atrazine affects the methylation of PHLDB2 gene | CTD | PMID:35440735 | PHLDB2 | Human | benzo[a]pyrene | decreases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of PHLDB2 mRNA | CTD | PMID:19770486 | PHLDB2 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of PHLDB2 exon and Benzo(a)pyrene affects the methylation of PHLDB2 promoter | CTD | PMID:27901495 and PMID:30157460 | PHLDB2 | Human | benzo[a]pyrene | decreases methylation | EXP | | 6480464 | Benzo(a)pyrene results in decreased methylation of PHLDB2 5' UTR | CTD | PMID:27901495 | PHLDB2 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of PHLDB2 protein | CTD | PMID:32717239 | PHLDB2 | Human | benzo[a]pyrene diol epoxide I | decreases expression | EXP | | 6480464 | 7 more ... | CTD | PMID:19150397 and PMID:20382639 | PHLDB2 | Human | bisphenol A | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | bisphenol A results in increased expression of PHLDB2 mRNA | CTD | PMID:26063408 more ... | PHLDB2 | Human | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of PHLDB2 gene | CTD | PMID:31601247 | PHLDB2 | Human | bisphenol A | affects methylation | EXP | | 6480464 | bisphenol A affects the methylation of PHLDB2 gene | CTD | PMID:31601247 | PHLDB2 | Human | bisphenol A | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of PHLDB2 mRNA | CTD | PMID:25181051 more ... | PHLDB2 | Human | bisphenol F | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | bisphenol F results in increased expression of PHLDB2 mRNA | CTD | PMID:30951980 | PHLDB2 | Human | butanal | decreases expression | EXP | | 6480464 | butyraldehyde results in decreased expression of PHLDB2 mRNA | CTD | PMID:26079696 | PHLDB2 | Human | cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of PHLDB2 mRNA | CTD | PMID:26472689 | PHLDB2 | Human | caffeine | affects phosphorylation | EXP | | 6480464 | Caffeine affects the phosphorylation of PHLDB2 protein | CTD | PMID:35688186 | PHLDB2 | Human | calcitriol | increases expression | EXP | | 6480464 | Calcitriol results in increased expression of PHLDB2 mRNA | CTD | PMID:16002434 | PHLDB2 | Human | cannabidiol | increases expression | EXP | | 6480464 | Cannabidiol results in increased expression of PHLDB2 mRNA | CTD | PMID:33244087 | PHLDB2 | Human | carbamazepine | affects expression | EXP | | 6480464 | Carbamazepine affects the expression of PHLDB2 mRNA | CTD | PMID:25979313 | PHLDB2 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to PHLDB2 gene] | CTD | PMID:28238834 | PHLDB2 | Human | chlorpyrifos | decreases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Chlorpyrifos results in decreased expression of PHLDB2 mRNA | CTD | PMID:37019170 | PHLDB2 | Human | choline | multiple interactions | ISO | Phldb2 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PHLDB2 gene | CTD | PMID:20938992 | PHLDB2 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of PHLDB2 mRNA | CTD | PMID:27392435 | PHLDB2 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of PHLDB2 mRNA | CTD | PMID:27392435 | PHLDB2 | Human | cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of PHLDB2 mRNA | CTD | PMID:19320972 | PHLDB2 | Human | copper atom | multiple interactions | EXP | | 6480464 | [Disulfiram binds to Copper] which results in increased expression of PHLDB2 mRNA | CTD | PMID:24690739 | PHLDB2 | Human | copper(0) | multiple interactions | EXP | | 6480464 | [Disulfiram binds to Copper] which results in increased expression of PHLDB2 mRNA | CTD | PMID:24690739 | PHLDB2 | Human | copper(II) sulfate | decreases expression | EXP | | 6480464 | Copper Sulfate results in decreased expression of PHLDB2 mRNA | CTD | PMID:19549813 | PHLDB2 | Human | coumarin | decreases phosphorylation | EXP | | 6480464 | coumarin results in decreased phosphorylation of PHLDB2 protein | CTD | PMID:35688186 | PHLDB2 | Human | coumestrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | PHLDB2 | Human | crocidolite asbestos | decreases expression | EXP | | 6480464 | Asbestos and Crocidolite results in decreased expression of PHLDB2 mRNA | CTD | PMID:29523930 | PHLDB2 | Human | crocidolite asbestos | decreases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Asbestos and Crocidolite results in decreased expression of PHLDB2 mRNA | CTD | PMID:29279043 | PHLDB2 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of PHLDB2 mRNA | CTD | PMID:20106945 | PHLDB2 | Human | cyclosporin A | affects expression | EXP | | 6480464 | Cyclosporine affects the expression of PHLDB2 mRNA | CTD | PMID:25562108 | PHLDB2 | Human | dexamethasone | decreases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Dexamethasone results in decreased expression of PHLDB2 mRNA | CTD | PMID:22733784 | PHLDB2 | Human | diarsenic trioxide | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of PHLDB2 mRNA | CTD | PMID:20458559 | PHLDB2 | Human | dibutyl phthalate | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Dibutyl Phthalate results in increased expression of PHLDB2 mRNA | CTD | PMID:17361019 and PMID:21266533 | PHLDB2 | Human | disulfiram | multiple interactions | EXP | | 6480464 | [Disulfiram binds to Copper] which results in increased expression of PHLDB2 mRNA | CTD | PMID:24690739 | PHLDB2 | Human | diuron | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Diuron results in decreased expression of PHLDB2 mRNA | CTD | PMID:25152437 | PHLDB2 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDB2 mRNA | CTD | PMID:27188386 | PHLDB2 | Human | Enterolactone | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHLDB2 mRNA | CTD | PMID:19167446 | PHLDB2 | Human | ethyl methanesulfonate | decreases expression | EXP | | 6480464 | Ethyl Methanesulfonate results in decreased expression of PHLDB2 mRNA | CTD | PMID:23649840 | PHLDB2 | Human | fenamidone | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | fenamidone results in increased expression of PHLDB2 mRNA | CTD | PMID:27029645 | PHLDB2 | Human | folic acid | multiple interactions | ISO | Phldb2 (Mus musculus) | 6480464 | [1 more ... | CTD | PMID:20938992 and PMID:22206623 | PHLDB2 | Human | FR900359 | affects phosphorylation | EXP | | 6480464 | FR900359 affects the phosphorylation of PHLDB2 protein | CTD | PMID:37730182 | PHLDB2 | Human | fulvestrant | increases methylation | EXP | | 6480464 | Fulvestrant results in increased methylation of PHLDB2 gene | CTD | PMID:31601247 | PHLDB2 | Human | fulvestrant | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of PHLDB2 gene | CTD | PMID:31601247 | PHLDB2 | Human | geldanamycin | increases expression | EXP | | 6480464 | geldanamycin results in increased expression of PHLDB2 mRNA | CTD | PMID:26705709 | PHLDB2 | Human | glyphosate | decreases methylation | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Glyphosate results in decreased methylation of PHLDB2 gene | CTD | PMID:31011160 | PHLDB2 | Human | hexadecanoic acid | decreases phosphorylation | EXP | | 6480464 | Palmitic Acid results in decreased phosphorylation of PHLDB2 protein | CTD | PMID:28073184 | PHLDB2 | Human | isobutanol | multiple interactions | EXP | | 6480464 | [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PHLDB2 mRNA | CTD | PMID:29432896 | PHLDB2 | Human | ivermectin | decreases expression | EXP | | 6480464 | Ivermectin results in decreased expression of PHLDB2 protein | CTD | PMID:32959892 | PHLDB2 | Human | L-methionine | multiple interactions | ISO | Phldb2 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PHLDB2 gene | CTD | PMID:20938992 | PHLDB2 | Human | Licochalcone B | decreases expression | EXP | | 6480464 | licochalcone B results in decreased expression of PHLDB2 mRNA | CTD | PMID:33647349 | PHLDB2 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of PHLDB2 mRNA | CTD | PMID:35811015 | PHLDB2 | Human | melphalan | decreases expression | EXP | | 6480464 | Melphalan results in decreased expression of PHLDB2 mRNA | CTD | PMID:22363485 | PHLDB2 | Human | nefazodone | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | nefazodone results in decreased expression of PHLDB2 mRNA | CTD | PMID:24136188 | PHLDB2 | Human | nimesulide | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | nimesulide results in decreased expression of PHLDB2 mRNA | CTD | PMID:24136188 | PHLDB2 | Human | ochratoxin A | decreases expression | EXP | | 6480464 | ochratoxin A results in decreased expression of PHLDB2 mRNA | CTD | PMID:30559759 | PHLDB2 | Human | paracetamol | affects expression | ISO | Phldb2 (Mus musculus) | 6480464 | Acetaminophen affects the expression of PHLDB2 mRNA | CTD | PMID:17562736 | PHLDB2 | Human | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of PHLDB2 mRNA | CTD | PMID:21420995 | PHLDB2 | Human | phenobarbital | affects expression | ISO | Phldb2 (Mus musculus) | 6480464 | Phenobarbital affects the expression of PHLDB2 mRNA | CTD | PMID:23091169 | PHLDB2 | Human | pirinixic acid | decreases expression | ISO | Phldb2 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of PHLDB2 mRNA | CTD | PMID:18445702 | PHLDB2 | Human | quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of PHLDB2 mRNA | CTD | PMID:21632981 | PHLDB2 | Human | rac-lactic acid | increases expression | EXP | | 6480464 | Lactic Acid results in increased expression of PHLDB2 mRNA | CTD | PMID:30851411 | PHLDB2 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of PHLDB2 mRNA | CTD | PMID:19167446 | PHLDB2 | Human | rotenone | increases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Rotenone results in increased expression of PHLDB2 mRNA | CTD | PMID:28374803 | PHLDB2 | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of PHLDB2 mRNA | CTD | PMID:35811015 | PHLDB2 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDB2 mRNA | CTD | PMID:27188386 | PHLDB2 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide analog results in increased expression of PHLDB2 mRNA | CTD | PMID:25895662 | PHLDB2 | Human | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of PHLDB2 mRNA | CTD | PMID:28959546 | PHLDB2 | Human | silver atom | decreases expression | EXP | | 6480464 | Silver results in decreased expression of PHLDB2 mRNA | CTD | PMID:26551752 | PHLDB2 | Human | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of PHLDB2 mRNA | CTD | PMID:28959546 | PHLDB2 | Human | silver(0) | decreases expression | EXP | | 6480464 | Silver results in decreased expression of PHLDB2 mRNA | CTD | PMID:26551752 | PHLDB2 | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of PHLDB2 mRNA | CTD | PMID:12679051 more ... | PHLDB2 | Human | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of PHLDB2 mRNA | CTD | PMID:31533062 | PHLDB2 | Human | tetrachloromethane | affects expression | ISO | Phldb2 (Mus musculus) | 6480464 | Carbon Tetrachloride affects the expression of PHLDB2 mRNA | CTD | PMID:17484886 and PMID:31919559 | PHLDB2 | Human | tetrachloromethane | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Carbon Tetrachloride results in decreased expression of PHLDB2 mRNA | CTD | PMID:31150632 | PHLDB2 | Human | tetrachloromethane | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of PHLDB2 mRNA | CTD | PMID:27339419 | PHLDB2 | Human | thimerosal | decreases expression | EXP | | 6480464 | Thimerosal results in decreased expression of PHLDB2 mRNA | CTD | PMID:27188386 | PHLDB2 | Human | thioacetamide | affects expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Thioacetamide affects the expression of PHLDB2 mRNA | CTD | PMID:34492290 | PHLDB2 | Human | thiram | decreases expression | EXP | | 6480464 | Thiram results in decreased expression of PHLDB2 mRNA | CTD | PMID:38568856 | PHLDB2 | Human | titanium dioxide | affects expression | ISO | Phldb2 (Mus musculus) | 6480464 | titanium dioxide affects the expression of PHLDB2 mRNA | CTD | PMID:23557971 | PHLDB2 | Human | titanium dioxide | decreases methylation | ISO | Phldb2 (Mus musculus) | 6480464 | titanium dioxide results in decreased methylation of PHLDB2 gene | CTD | PMID:35295148 | PHLDB2 | Human | trichloroethene | decreases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | Trichloroethylene results in decreased expression of PHLDB2 mRNA | CTD | PMID:33387578 | PHLDB2 | Human | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of PHLDB2 mRNA | CTD | PMID:24935251 | PHLDB2 | Human | triclosan | increases expression | EXP | | 6480464 | Triclosan results in increased expression of PHLDB2 mRNA | CTD | PMID:30510588 | PHLDB2 | Human | triphenyl phosphate | increases expression | ISO | Phldb2 (Rattus norvegicus) | 6480464 | triphenyl phosphate results in increased expression of PHLDB2 mRNA | CTD | PMID:30589522 | PHLDB2 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of PHLDB2 mRNA | CTD | PMID:37042841 | PHLDB2 | Human | triptonide | increases expression | ISO | Phldb2 (Mus musculus) | 6480464 | triptonide results in increased expression of PHLDB2 mRNA | CTD | PMID:33045310 | PHLDB2 | Human | troglitazone | decreases expression | EXP | | 6480464 | troglitazone results in decreased expression of PHLDB2 mRNA | CTD | PMID:25572481 | PHLDB2 | Human | urethane | decreases expression | EXP | | 6480464 | Urethane results in decreased expression of PHLDB2 mRNA | CTD | PMID:28818685 | PHLDB2 | Human | valproic acid | decreases methylation | EXP | | 6480464 | Valproic Acid results in decreased methylation of PHLDB2 gene | CTD | PMID:29154799 | PHLDB2 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of PHLDB2 mRNA | CTD | PMID:25979313 | PHLDB2 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of PHLDB2 mRNA | CTD | PMID:23179753 more ... | PHLDB2 | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDB2 mRNA | CTD | PMID:27188386 | PHLDB2 | Human | vorinostat | affects expression | EXP | | 6480464 | vorinostat affects the expression of PHLDB2 mRNA | CTD | PMID:27188386 | |